BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 10, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ALN-VSP: Interim Phase I data

Interim data from tumor biopsies from 8 patients in an open-label, dose-escalation Phase I trial showed that 0.4-1.25 mg/kg IV ALN-VSP produced ALN-VSP concentrations of 0.3-142 ng/g tissue, which Alnylam said was "pharmacologically relevant." Additionally, 2 of 3 patients who received the 0.4 mg/kg dose showed evidence of RNAi-mediated VEGF mRNA cleavage.

Alnylam previously reported data from 12 evaluable patients who received...

Read the full 293 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >